Holen Sie sich die Stockscreener-App
2.75
3.00%
0.08
Schlusskurs vom Vortag:
$2.67
Offen:
$2.68
24-Stunden-Volumen:
134.18K
Relative Volume:
1.65
Marktkapitalisierung:
$35.32M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-70.20M
KGV:
-0.0614
EPS:
-44.82
Netto-Cashflow:
$-50.66M
1W Leistung:
+8.70%
1M Leistung:
+0.00%
6M Leistung:
-36.05%
1J Leistung:
+0.00%
1-Tages-Spanne:
$2.63
$2.80
1-Wochen-Bereich:
$2.445
$2.85
52-Wochen-Spanne:
$1.70
$19.40
Onkure Therapeutics Inc Stock (OKUR) Company Profile
Firmenname
Onkure Therapeutics Inc
Sektor
Branche
Telefon
(720) 307-2892
Adresse
6707 WINCHESTER CIRCLE, SUITE 400, BOULDER
Vergleichen Sie OKUR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OKUR
Onkure Therapeutics Inc
|
2.75 | 36.12M | 0 | -70.20M | -50.66M | -44.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Onkure Therapeutics Inc Stock (OKUR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-30 | Eingeleitet | Evercore ISI | Outperform |
| 2024-12-05 | Eingeleitet | Leerink Partners | Outperform |
| 2024-10-10 | Eingeleitet | Oppenheimer | Outperform |
| 2023-12-15 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-12-15 | Herabstufung | Jefferies | Buy → Hold |
| 2023-12-15 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2023-12-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2023-12-14 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2023-12-14 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-12-14 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2023-12-14 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-11-15 | Eingeleitet | William Blair | Outperform |
| 2023-08-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-07-03 | Eingeleitet | BofA Securities | Buy |
| 2022-09-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-01-27 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-12-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-22 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2021-05-04 | Eingeleitet | Jefferies | Buy |
| 2021-05-04 | Eingeleitet | Piper Sandler | Overweight |
| 2021-05-04 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Onkure Therapeutics Inc Aktie (OKUR) Neueste Nachrichten
Relative strength of OnKure Therapeutics Inc. in sector analysisMarket Movers & Advanced Swing Trade Entry Plans - newser.com
What data driven models say about OnKure Therapeutics Inc.’s futureMarket Growth Summary & High Accuracy Trade Signal Alerts - newser.com
Using Python tools to backtest OnKure Therapeutics Inc. strategiesJuly 2025 Technicals & Entry Point Strategy Guides - newser.com
OnKure Therapeutics Inc. stock volume spike explainedJuly 2025 Gainers & Expert Approved Momentum Trade Ideas - newser.com
Applying Wyckoff theory to OnKure Therapeutics Inc. stockWeekly Investment Recap & Fast Exit and Entry Strategy Plans - newser.com
Can trapped investors hope for a rebound in OnKure Therapeutics Inc.Gap Down & Weekly High Potential Alerts - newser.com
How OnKure Therapeutics Inc. stock trades before earningsWeekly Volume Report & Growth Focused Investment Plans - newser.com
What analysts say about OnKure Therapeutics Inc stockTrading Volume Surges & High Return Wealth Plans - earlytimes.in
What drives OnKure Therapeutics Inc stock priceGrowth vs. Value Investing & You’ve Never Seen Stock Picks Like These - earlytimes.in
Advanced analytics toolkit walkthrough for OnKure Therapeutics Inc.Portfolio Growth Summary & Stepwise Trade Execution Plans - newser.com
LifeSci Capital Maintains OnKure Therapeutics(OKUR.US) With Buy Rating, Raises Target Price to $21 - 富途牛牛
OnKure Therapeutics CEO Saccomano sells $230 in stock By Investing.com - Investing.com Australia
OnKure Therapeutics CEO Saccomano sells $230 in stock - Investing.com India
OKUR SEC FilingsOnKure Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
Quantitative breakdown of OnKure Therapeutics Inc. recent movePortfolio Return Summary & AI Powered Trade Plan Recommendations - newser.com
Can OnKure Therapeutics Inc. recover in the next quarterJuly 2025 Outlook & Daily Entry Point Alerts - newser.com
Backtesting results for OnKure Therapeutics Inc. trading strategiesEarnings Overview Summary & Stock Portfolio Risk Management - newser.com
Does OnKure Therapeutics Inc have high return on assets2025 Trading Recap & Risk Controlled Stock Pick Alerts - khodrobank.com
Published on: 2025-09-20 08:05:52 - خودرو بانک
Detecting price anomalies in OnKure Therapeutics Inc. with AIPortfolio Gains Report & Weekly Stock Performance Updates - newser.com
Published on: 2025-09-20 05:11:15 - khodrobank.com
Finanzdaten der Onkure Therapeutics Inc-Aktie (OKUR)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.36%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):